%J The Lancet Microbe
%T Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes
%A Tom A Yates
%A Daniel J Grint
%O Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
%L discovery10206194
%D 2025
%I Elsevier BV